Navigation Links
For Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabThera's Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
Date:8/30/2010

used in preference to the brand if the price differences are favorable and efficacy/safety are the same as the brand.

The report is based on a survey of 251 hematologist-oncologists from Germany (52), France (50), Italy (49), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

WebinarMedia members are welcome to attend our upcoming webinar based on this report entitled European Clinician and Payer Perspectives on the Dominance of Roche's MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? This online presentation will be held on September 22, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at ccomfort@dresources.com.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... June 4 Mylan Inc. (Nasdaq: MYL ) ... approval from the U.S. Food and Drug Administration (FDA) for its ... and 800 mg, the generic version of Pfizer,s Neurontin® Tablets for ... will be distributed by Mylan Pharmaceuticals Inc. , ...
... June 4 Syndax Pharmaceuticals, Inc., a ... Phase 2, open-label ENCORE 303 trial in post-menopausal women ... were progressing on aromatase inhibitor (AI) therapy. Safety and ... a poster at the American Society of Clinical Oncology ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Neurontin® Tablets 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 3Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 4
(Date:7/11/2014)... University has revealed that people who have grown up ... likely as their urban counterparts to develop the most ... The study findings have recently been published in the ... extremely exciting that we can now see that not ... appear to depend on the environment we are exposed ...
(Date:7/11/2014)... July 11, 2014 Recently, iFitDress.com, a ... occasion outfits, has released its new collection of ... the company has announced that all these beautiful items ... The deadline of the special offer is July 22. ... major officials pay close attention to customer satisfaction. On ...
(Date:7/11/2014)... Los Angeles dental implant expert ... and full mouth implants to replace missing teeth. Both ... dental implants from other tooth replacements: They replace the ... alone prevents the long-term complications of missing teeth, but ... comfort, appearance and systemic health. Mini implants broaden candidacy ...
(Date:7/11/2014)... Maureen Salamon HealthDay Reporter ... For the millions of women who can,t cough, sneeze ... a treatment that uses stem cells to regenerate weakened ... researchers found that injecting stem cells isolated from patients, ... all participants within a year. Stress incontinence ...
(Date:7/11/2014)... Grants Pass, OR (PRWEB) July 11, 2014 ... understanding of life, health, the atmosphere, and how water affects ... Fourth Phase Water, Gerald Pollack, during an interview on the ... 7, 2014. , Gerald Pollack, PhD, is ... latest book is The Fourth Phase of Water (Ebner & ...
Breaking Medicine News(10 mins):Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 3Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 3
... leave poses a significant barrier, experts say , SUNDAY, ... of American moms start their infants on human milk, ... months of life, let alone an entire year. ... can prove difficult for new moms, but California researchers ...
... ... launched a 5 year campaign to raise funds internationally to assist people living ... unique opportunity for everyone to help support children born with this life threatening ... The CF Worldwide goal is to have 50,000 members join the campaign and ...
... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
... ... Ally Maize and Richard Maize ventured out on a cool evening in the spirit of Hanukkah ... hungry. It was a night that was going to change their lives. , ... Los Angeles, CA (PRWEB) December 25, 2009 -- Richard Maize ...
... , ... bring together nanotechnology to focus on Sports injury prevention and training , ... Mission Viejo, Calif. (PRWEB) December ... its first subsidiary for sports based technologies called MVP Sports Technologies, Inc., , ,MVP ...
... occurring lipid appears to protect against RSV, research shows , ... the lungs appears to have the ability to prevent infection ... of infection in babies and can also be dangerous for ... researchers report. , The lipid, known as POPG, seems to ...
Cached Medicine News:Health News:Many Women Quit Breast-Feeding Early 2Health News:Many Women Quit Breast-Feeding Early 3Health News:Cystic Fibrosis Worldwide Launches a New Campaign to Reach Thousands Who Suffer from CF 2Health News:Cystic Fibrosis Worldwide Launches a New Campaign to Reach Thousands Who Suffer from CF 3Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Richard Maize Inspires Wealthy to Aid Homeless During Hanukkah, Christmas 2Health News:Richard Maize Inspires Wealthy to Aid Homeless During Hanukkah, Christmas 3Health News:Richard Maize Inspires Wealthy to Aid Homeless During Hanukkah, Christmas 4Health News:Richard Maize Inspires Wealthy to Aid Homeless During Hanukkah, Christmas 5Health News:Applied Technology Holdings, Inc. Forms First New Subsidiary Called MVP Sports Technologies, Inc. 2Health News:Discovery in Lungs May Lead to Treatment for Respiratory Virus 2
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
... have become the accepted standard for,excellence and ... AML Total Hip System was the first ... meet the needs for biological fixation in ... 15 years of documented clinical performance, the ...
Medicine Products: